Singclean & Dr. Matt Stefanelli—Promoting innovation in the global medical aesthetics field
singclean | 2024-03-11
Singclean invited Dr. Matt Stefanelli , world famous reconstructive & aesthetic surgeon, to share the injection application of Singfiller and Singderm combined with the latest anatomical technology. It is a big success! In the future, Singclean and Dr. Matt will join hands to launch more medical aesthetic teaching projects, and promote new breakthroughs in the global medical aesthetic industry!
Further Articles
-
singclean | 2024-03-11
Headlining FIGO 2025: A Can’t-Miss Keynote by Prof. Osama Shawki, Presented by Singclean & KSMSingclean, in partnership with Kayan Al-Seha Medical (KSM), will debut at FIGO 2025 in Cape Town with a keynote lecture by renowned gynecologist Professor Osama Shawki. His session will spotlight innovations in hysteroscopy and adhesion prevention, showcasing Singclean’s commitment to advancing women’s healthcare worldwide. -
singclean | 2024-03-11
Singclean Draws Major Attention at ESCRS 2025 with Advanced Viscoelastic Solution for Ophthalmic SurgeryCOPENHAGEN, DENMARK – Hangzhou Singclean Medical Products Co., Ltd. made a strong impression at the 45th ESCRS Congress (European Society of Cataract and Refractive Surgeons), held September 12–16, 2025, at the Bella Center in Copenhagen. Recognized globally for its high professional standards and influence in ophthalmology, the congress gathered leading industry manufacturers, surgeons, and specialists from around the world. -
singclean | 2024-03-11
Singderm Filler Achieves 92.7% Efficacy at 12 Months in Global Clinical Trial, Validated by Landmark Thailand MasterclassBangkok, Thailand – Singderm, a globally certified dermal filler brand, has demonstrated unprecedented clinical performance in its Thailand Masterclass led by renowned physician Dr. Worawat Nolah. Three top KOLs (Hack Anantaya, Chalidaorn PinNy, Thantaya Thuranuch) received multi-zone injections with zero complications, reinforcing Singderm’s 92.7% 12-month efficacy rate from a 100-subject clinical trial.
